Papillary thyroid carcinoma (PTC) accounts for 480% thyroid malignancies, and BRAF V600E mutation is frequently found in 440% PTC. Interleukin-12 (IL-12) is a proinflammatory heterodimeric cytokine with strong antitumor activity. It is not known whether IL-12 immunotherapy is effective against Braf V600E -induced PTC. In the present study, we investigated the effectiveness of IL-12 immunotherapy against Braf
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-induced PTC in LSL-Braf V600E /TPO-Cre mice. LSL-Braf V600E /TPO-Cre mice were created for thyroid-specific expression of Braf V600E under the endogenous Braf promoter, and spontaneous PTC developed at about 5 weeks of age. The mice were subjected to two treatment regimens: (1) weekly intramuscular injection of 50 μg plasmid DNA expressing a single-chain IL-12 fusion protein (scIL-12/CMVpDNA), (2) daily intraperitoneal injection of mouse recombinant IL-12 protein (mrIL-12, 100 ng per day). The role of T cells, natural killer (NK) cells, and transforming growth factor-β (TGF-β) in IL-12-mediated antitumor effects was determined by a 51 Cr-release cytotoxicity assay. Tumor size and weight were significantly reduced by either weekly intramuscular injection of scIL-12/CMVpDNA or daily intraperitoneal injection of mrIL-12, and tumor became more localized. Survival was significantly increased when treatment started at 1 week of age as compared with that at the 6 weeks of age. Both NK and CD8 + T cells were involved in the cytotoxicity against tumor cells and their antitumor activity was significantly reduced in tumor-bearing mice. TGF-β also inhibited the antitumor activity of NK and CD8 + T cells. The immune suppression was completely reversed by IL-12 treatment and partially recovered by anti-TGF-β antibody. We conclude that both IL-12 gene therapy and recombinant protein therapy are effective against PTC. Given that the immune response is significantly suppressed in tumor-bearing mice and can be restored by IL-12, the current study raises a possibility of the application of IL-12 as an adjuvant therapy for thyroid cancer. Thyroid cancer is the most common malignancy in the endocrine system and its incidence has been rising in recent years. 1 It is commonly classified into papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and anaplastic thyroid carcinoma (ATC). PTC is the most common type of differentiated thyroid carcinoma, accounting for 480% of thyroid malignancies. 2 Differentiated (PTC and FTC) thyroid cancer has relatively good prognosis, whereas ATC is highly aggressive and most patients die within 1 year of the diagnosis. Most differentiated thyroid cancers can be cured by surgery and 131 I therapy. However, 10-20% of patients die from recurrence or progression into poorly differentiated tumors refractory to classical treatments such as suppression of serum thyroid-stimulating hormone by thyroxine following surgery and radioiodine therapy. [3] [4] [5] To treat these patients, it becomes necessary to search for new treatment strategies such as tyrosine kinase inhibitors and immunotherapy. BRAF V600E mutation is frequently found in PTC with an overall rate of 42% and has been associated with recurrence and poor prognosis. 6 To treat patients with recurrent or poorly differentiated PTC, novel approaches have been explored: for example, by targeting RAS-RAF-MEK-ERK MAP kinase signaling pathway using Sorafenib (BAY 43-9006, an inhibitor of multiple receptor tyrosine kinases), [7] [8] [9] [10] vascular endothelial growth factor receptor signaling using Lenvatinib, 11 or targeting AKT/mammalian target of rapamycin pathway. 12 Although these approaches produced promising results, and Sorafenib and Lenvatinib have been approved recently by FDA for the treatment of patients with recurrent or metastatic radioactive iodine-refractory differentiated thyroid cancer, immunotherapy has not been explored in these patients. In our previous studies, we have demonstrated that IL-12 is effective against ATC in a mouse xenograft model. 13 The antitumor activity of IL-12 has not been investigated in genetically engineered mouse models, which are often regarded as superior to the xenograft models. 14 
Establishment of a Thyroid Tumor Cell Line
A PTC tumor from a 4-month-old LSL-Braf V600E /TPO-Cre mouse was harvested aseptically using blunt dissection. The tumor was then mechanically dissociated by mincing and passing through a 40-μM mesh sterile screen, and suspended in DMEM/F12 growth medium (10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin). Cells were further dissociated by incubation in growth medium containing 100 U/ml type I collagenase (Sigma-Aldrich) and 1.0 U/ml dispase I (Roche Diagnostics, Indianapolis, IN, USA) at 37°C in a rocking water bath for 60 min. The cell suspension was washed two times with growth media and resuspended in a 10-mm culture dish with DMEM/F12 growth medium containing 2 mU/ml bovine TSH (Sigma-Aldrich) to establish a BVE cell line (Braf V600E -induced tumor cell line). The BVE cell line was tested to be tumorigenic after injection of 10 6 cells subcutaneously into the nude mice. The thyroid origin of the cell line was confirmed by thyroid-specific gene expression of Tshr, Tg, and Slc5a5 and PCR-based genotyping, which shows thyroid-specific 518 bp Lox-Braf V600E fragment (Supplementary Figure 1) .
Detection of Thyroid-Specific Gene Expression
The Tshr, Tg, and Slc5a5 gene expression in the thyroid tumor cell line was detected by RT-PCR using the following primers: (1) the Tshr gene (NM_011648, thyrotropin receptor): 5′-TCTGCTGCTCGCCCTGTCCAGG-3′ (forward, in exon 1) and 5′-GGTATGGTCTTCAGATGAGTCT-3′ (reverse, in exon 2). The primer pairs span 92 kb of intron 1 and amplify a 174 bp cDNA fragment); (2) the Tg gene (NM_009375, thyroglobulin): 5′-AGTACCAGGTAGATGCA CAGCC-3′ (forward, in exon 2) and 5′-CCAGCTGCCTG CTGCCAGGTA-3′ (reverse, in exon 3). The primer pairs span 945 bp of intron 2 and amplify a 192 bp cDNA fragment; (3) the Slc5a5 gene (NM_053248.2, sodium iodide symporter): 5′-GCATCGCTCCTGTCCACAGGAA-3′ (forward, in exon 4) and 5′-TCCATCAGGTTGATCCGGGAAT-3′ (reverse, in exon 5). The primer pairs span 742 bp of intron 4 and amplify a 203 bp cDNA fragment. The PCR conditions were 95°C for 5 min, followed by 35 cycles of amplification (95°C for 40 s, 50-62°C for 40 s, and 72°C for 40 s), with final extension at 72°C for 5 min. The resulting PCR products were analyzed by gel electrophoresis. Each successfully amplified fragment was directly sequenced using the BigDye Terminator V3.1 Cycle Sequencing Kit and ABI Prism 3100 Sequencer (Applied Biosystems, Foster City, CA, USA).
TSH Measurements
Blood was collected by cardiac puncture. Serum TSH was measured using MILLIPLEX MAP Mouse Pituitary Magnetic Bead Panel following the manufacturer's instruction (EMD Millipore Corporation, Billerica, MA, USA).
IL-12 Gene Therapy Against Established Thyroid Tumors in LSL-Braf
V600E /TPO-Cre Mice Fifty micrograms of plasmid DNA expressing single-chain mouse IL-12 fusion protein (scIL-12/CMVpDNA) in 50 μl PBS were injected into the rectus femoris muscle of hind leg per animal as described previously. 13, 20 Ten mice in the treatment group received weekly intramuscular injection of scIL-12/CMVpDNA for 2 months starting from 6 to 8 weeks of age. The same number of mice in the control group received weekly intramuscular injection of vector DNA (CMVpDNA). Mice were observed for survival and killed at the end of 12 months. Tumor load and histology were examined and compared with controls.
Recombinant IL-12 Therapy Against Established Thyroid Tumors in LSL-Braf V600E /TPO-Cre Mice The half-life of rIL-12 is about 5-10 h and daily injection is required to reach effective serum level. Ten mice received daily intraperitoneal injection of recombinant IL-12 (R&D Systems, Minneapolis, MN, USA) for 5 days (100 ng IL-12 per day in 50 μl PBS), followed by 2-day rest for a total of 40 injections starting from 6 to 8 weeks of age. The same number of mice in the control group received only daily injection of 50 μl PBS. Mice were observed for survival and killed at the end of 12 months. Thyroid tumor load and histology were examined and compared with controls.
Recombinant IL-12 Therapy To Prevent Thyroid Tumorigenesis in LSL-Braf V600E /TPO-Cre Mice Ten mice received daily intraperitoneal injection of recombinant IL-12 for 5 days, followed by 2-day rest for a total of 40 injections starting from day 7 after birth. Half dosage (50 ng IL-12 in 25 μl PBS per day) was given for the first 3 weeks and normal dosage (100 ng IL-12 in 50 μl PBS per day) for the rest of the treatment. Control mice were injected with PBS only. Mice were observed for survival and killed at the end of 12 months.
Histology and Immunohistochemistry
Histology and immunohistochemical staining was described previously. 21 Briefly, 4-μm-thick formalin-fixed, paraffinembedded tissue sections were prepared and stained with hematoxylin and eosin or anti-CD68 (pan-macrophage marker), anti-CD80 (M1 macrophage marker), and anti-CD206 (M2 macrophage marker) antibodies, respectively (BioLegend, San Diego, CA, USA). Dako LSAB+Kit, HRP was used for immunostaining (Dako, Carpinteria, CA, USA). The sections were counterstained with Mayer's hematoxylin.
NK Cell Assay and Phenotyping of Effector Cells
Cr-release assay was used to measure the specific cytotoxicity of spleen cells at different effector/target ratios as described previously. [22] [23] [24] The killer cells were immune phenotyped for the presence of surface markers: Thy1, Lyt2, L3/T4, and asialo-GM-1 (aGM1) by using complementmediated (Cederlane Low-Tox-M Rabbit Complement, 1:20 dilution) cytotoxicity assay in the presence of appropriate antibodies. Briefly, spleen cells (effector cells) were harvested and pooled from six 12-week-old LSL-Braf V600E /TPO-Cre mice (tumor-bearing mice) or three LSL-Braf WT /TPO-Cre mice (normal control) with or without IL-12 treatment (100 ng, intraperitoneal injection for 5 days). BVE cells (target cells at 1 × 10 6 ) were labeled with 100 μCi Na 51 CrO 4 (Perkin-Elmer, Waltham, MA, USA) for 2 h at 37°C. The target cells were then washed two times in a culture medium and resuspended at 5000 cells per well in a 96-well roundbottomed plate. The effector cells were added to the target cells at various effector to target (E:T) ratios in the presence or absence of anti-mouse CD90.2 (Thy1.2, a pan T-cell marker), CD8 (Lyt2), and CD4 (L3/T4) antibodies at 1:20 dilution, and anti-mouse asialo GM1 (anti-NK cell antibody) at 1:200 dilution (Cedarlane, Burlington, ON, Canada). Different concentrations of transforming growth factor-β1 (TGF-β1) antibody (R&D Systems, Abingdon, UK) were also used to investigate its role in tumor target cell killing. After 4 h incubation at 37°C and 45 min in the presence of complement, 100 μl supernatants were collected and counted with an automatic gamma counter (Canberra-Packard Cobra 5002, Burladingen, Germany). 
Statistical Analyses
Tumor load and cytotoxicity among different treatment groups were analyzed using the Student's t-test or repeated measures ANOVA and Bonferroni post-test when appropriate. Kaplan-Meier analysis was used to calculate survival. Differences were considered statistically significant when the P-value was o0.05.
RESULTS

IL-12 Immunotherapy to Treat Established PTC
We used two approaches to evaluate IL-12 immunotherapy against PTC: IL-12 gene therapy and IL-12 recombinant protein therapy. IL-12 gene therapy produced persistent low levels of serum IL-12 that peaked at day 6 and last~2 weeks after single intramuscular injection (Supplementary Figure 2) . By contrast, IL-12 recombinant protein therapy resulted in much higher levels of serum IL-12, which were peaked at 2 h and rapidly cleared within 10 h (Supplementary Figure 2) . Thus, daily intraperitoneal injection was required to maintain serum IL-12 level. Twenty LSL-Braf V600E /TPO-Cre mice (10 in each group) were given either weekly IL-12 gene therapy or daily 100 ng IL-12 recombinant protein for 2 months. As shown in Figure 1a , the tumor load was reduced by 440% after 2-month IL-12 gene therapy or IL-12 recombinant protein therapy (66.7 ± 6.0 mg in control vs 40 ± 3.3 mg in gene therapy or 37.5 ± 3.1 mg in IL-12 protein therapy group, Po0.01). Histologically, tumors became localized and more differentiated with the reappearance of follicular architecture (Figure 1b) . Mononuclear cells and macrophage infiltration were also observed (Figure 1b) , indicating that they were activated and mobilized for tumor clearance. Serum TSH levels were not significantly changed during IL-12 treatment. TSH was 450 000 pg/ml (beyond the detection limit of the kit) before and after treatment (n = 8) and is 4100-fold higher than LSL-Braf WT /TPO-Cre mice (n = 5, 394.3 ± 8.7 pg/ml). However, we could not completely rule out some effect of the treatment on the TSH responsiveness of the tumors in the model. The very high serum TSH levels precluded clear determination of a change in TSH levels that might have signaling effects. To evaluate whether IL-12 immunotherapy could affect the survival, 20 LSL-Braf V600E /TPO-Cre mice at the 6-8 weeks of age were treated with either weekly IL-12 gene therapy (n = 10) or daily IL-12 recombinant protein therapy (n = 10) for 2 months. The mice were monitored for 12 months. As shown in Figure 2a , the survival was significantly increased following IL-12 immunotherapy. Three mice were still alive at the end of the experiment following IL-12 protein therapy (Po0.01) and two mice were alive following IL-12 gene therapy (Po0.05). All the control mice died within 8 months because of tumor load/progression and hypothyroidism.
Effect of Early IL-12 Immunotherapy on Thyroid Tumorigenesis and Survival
To determine whether early IL-12 immunotherapy could prevent thyroid tumorigenesis or extend survival, we treated 10 LSL-Braf V600E /TPO-Cre mice with IL-12 recombinant protein at the age of 7 days for 2 months. The mice were 
carcinoma (PTC) tumors become localized (indicated by block arrows) after either recombinant IL-12 protein therapy (B and E) or IL-12 gene therapy (C and F). Reappearance of follicular architecture is observed with infiltration of many mononuclear cells and macrophages (indicated by arrows) (B).
Immunotherapy for Braf V600E -induced thyroid cancer RS Parhar et al monitors for 12 months. Although early immunotherapy could not prevent tumor development (all the mice had large tumors at the end of 12 months), it significantly prolonged the survival (Figure 2b ). Four mice in the treatment group were still alive at the end of 12 months, whereas all the control mice died within 9 months (Po0.01).
Cytolytic Activity of Immune Cells Induced by IL-12 Immunotherapy
To determine the mechanisms of IL-12-mediated antitumor activities, we measured cytolytic activity of splenocytes from various groups of mice treated with or without IL-12 against BVE tumor cells in a 4-h 51 Cr-release assay. As shown in Figure 3a , there was a significant reduction of splenocytesmediated cytotoxicity against tumor cells in the tumorbearing mice: 24.3 ± 1.1 (normal LSL-Braf WT /TPO-Cre mice) vs 1.4 ± 0.2 (tumor-bearing LSL-Braf V600E /TPO-Cre mice) at E:T ratio of 10, 38.6 ± 1.3 vs 3.7 ± 1.0 at E:T ratio of 25, and 65 ± 2.1 vs 10.6 ± 0.2 at E:T ratio of 50 (Po0.01), indicating that the splenic effector cell cytotoxicity from the tumorbearing mice was significantly suppressed. After IL-12 treatment, the effector cell cytotoxicity was substantially improved and was comparable to that from the wild-type mice ( Figure 3a) . Next, we investigated what kinds of immune effector cells were involved in the cytotoxicity against tumor cells. The cytotoxicity of splenocytes was significantly reduced in the presence of anti-CD8 (Po0.05) or anti-NK cell antibodies (Po0.01). No significant reduction was observed in the presence of anti-CD4 antibodies or anti-CD90.2 antibodies (P40.05) (Figure 3b ). These data indicate that CD8 + T and NK cells are major immune cells involved in the cytolytic activity against tumor cells.
Effect of TGF-β on the Cytotoxicity of Splenocytes Against Tumor Cells
Epithelial-mesenchymal transition is involved in the PTC progression from well-differentiated tumor to poorly differentiated tumor and TGF-β has been implicated in promoting this process. 25 As BVE tumor cells secrete higher level of TGF-β compared with normal thyroid cells (data not shown), TGF-β may be involved in the immune suppression of CD8 + T and NK cells in the tumor-bearing mice. We next investigated whether TGF-β has any role in inhibiting the cytolytic activity of CD8 + T and NK cells. Splenocytes from normal LSL-Braf WT /TPO-Cre mice were cultured in the presence of TGF-β, and the cytolytic activity of splenocytes against BVE tumor cells was measured in a 4-h 51 Cr-release assay. As shown in Figure 4a , TGF-β inhibited the cytolytic activity of splenocytes and it was dose-dependent (Po0.01). It also inhibited IL-12-mediated cytolytic activity of splenocytes against BVE tumor cells (Figure 4b ). We further investigated whether anti-TGF-β antibody could restore cytolytic activity of splenocytes from tumor-bearing mice. As shown in Figure 4c , the treatment with anti-TGF-β antibody partially restored cytolytic activity of splenocytes.
IL-12 Immunotherapy Increases M1 Tumor-Infiltrating Macrophages
Macrophages are master regulators of inflammation and can differentiate into M1 and M2 macrophages. 26 M1 macrophages are activated by lipopolysaccharide or T-helper 1 (Th1) produced interferon-γ. They secrete high levels of IL-12 and low levels of IL-10, and are involved in inflammation and tissue destruction. By contrast, M2 macrophages are activated by Th2 produced anti-inflammatory cytokines IL-4 and IL-10. They produce high levels of IL-10, TGF-β and low levels of IL-12. They are associated with tissue repair, The survival of the mice was monitored for 12 months. All the mice in the control group die within 9 months and 4 mice in the treatment group are still alive at the end of 12 months (Po0.01).
Immunotherapy for Braf V600E -induced thyroid cancer RS Parhar et al angiogenesis, and tumor promotion. Tumor-associated macrophages are mainly of the M2 phenotype. 27 To determine what type of macrophages was activated in the tumor tissue following IL-12 immunotherapy, we performed immunostaining of macrophages using three macrophage markers: CD68, CD80, and CD206. As shown in Figure 5 , very little macrophage infiltration is present in the tumor tissue before IL-12 therapy and they are mainly M2 macrophages (CD68+/CD80 − /CD206+). The ratio of M1/M2 is about 1/3. However, the M1 macrophages (CD68+/CD80+/CD206 − ) are significantly increased after IL-12 therapy. The M1/M2 ratio is reversed and is about 3/1.
DISCUSSION
We have demonstrated in the present study that IL-12 immunotherapy is effective against Braf V600E -induced PTC in a genetically engineered mouse model. The therapeutic effects of both IL-12 gene therapy and recombinant protein therapy are comparable and are mediated via CD8 + T and NK cells. Wennerberg et al. 28 have recently demonstrated that human anaplastic thyroid carcinoma (ATC) cells are also sensitive to NK cell-mediated lysis and ATC-derived NK cells display a suppressed phenotype with downregulated expression of NKG2D, which is an activating receptor expressed on CD8 + T and NK cells. 29 They further demonstrate that the suppression of NK cell-mediated lysis can be restored by blocking prostaglandin-E2, indicating Cox-2 inhibitors may have therapeutic benefit against ATC. However, the selective Cox-2 inhibitor celecoxib failed as a solitary agent (400 mg orally two times a day for 12 months) to treat patients with progressive metastatic differentiated thyroid cancer in an early clinical trial. 30 Given that the immune response is suppressed in tumor-bearing hosts (human and mouse), treatment strategies (such as IL-12 immunotherapy or Cox-2 inhibitors) to overcome immune suppression in combination with classic and targeted therapies should offer significant therapeutic benefits against thyroid cancer. The current study confirms in vivo that IL-12 immunotherapy is effective against PTC.
IL-12 is a 70 kDa disulfide-linked heterodimeric cytokine comprising two subunits, p35 (35 kDa) and p40 (40 kDa) subunits and mediates enhancement of the cytotoxic activity of CD8 + T and NK cells. 31, 32 It has a pivotal role in modulating the immune response by amplifying cytokine networks involved in the induction of Th1 cells while suppressing Th2 response. 33 Indeed, IL-12 possesses the most significant antitumor activity among all cytokines tested. We and others have shown the efficacy of IL-12 gene therapy with a single-chain IL-12 fusion construct created by linkage of the p35 and p40 cDNAs. 13, 34 The monomeric nature of single-chain IL-12 fusion protein ensures equal molar expression of each subunit, thereby avoiding the formation of p40 homodimers that antagonize IL-12 activity. 35 Although IL-12 has shown significant antitumor activities in many experimental animal models, 36 clinical trials with IL-12 used as a single agent in patients with advanced solid tumors and hematologic malignancies have shown mixed response rate ranging from 0 to 11%, except for cutaneous T-cell lymphoma, AIDS-related Kaposi sarcoma, and nonHodgkin's lymphoma where higher response rate is demonstrated. 37 This is probably because of the lower doses of IL-12 given to the patients because of severe dose-dependent systemic toxicity and higher tumor load (patients in advanced stage). The IL-12 dose used in the current study (daily intraperitoneal injection of 100 ng IL-12, around 4.5-7.7 μg/kg) is well tolerated in mice, which is 10 times higher than the 500 ng/kg tolerated in humans. 38 It has been shown that no tumor responses were seen at the 100 ng/kg, but partial or complete response was observed in Immunotherapy for Braf V600E -induced thyroid cancer RS Parhar et al 71% of Kaposi sarcoma patients receiving higher doses. 39 Furthermore, none of the patients in clinical trials received daily injection of IL-12 for 41 month, which may be required for showing therapeutic effects as a single agent given that its serum half-life is about 5-10 h. 40 In our current study, we have demonstrated that early systemic IL-12 treatment can significantly prolong survival when tumor load is low as compared with late treatment for established tumors. These data indicate that the application of IL-12 immunotherapy is more appropriate as an adjuvant therapy and should be used in combination with other treatment options such as surgery, radioactive iodine therapy, TSH suppression or targeted therapies against MAKP and/or PIK3/AKT signaling pathways.
Owing to toxicity of systemic administration of IL-12 in cancer patients, gene therapy offers advantage in reducing systemic side effects by local expression of IL-12 gene. The relatively low serum IL-12 levels would reduce systemic toxicity. It has been successfully used in both preclinical 41 and clinical trials. [42] [43] [44] The commonly used methods include intratumoral injection of IL-12 plasmid DNA, 43 peritumoral injection of IL-12-producing autologous fibroblasts 42 or autologous tumor cells, 45 and intratumoral injection of dendritic cells secreting interleukin-12. 44 The response rate ranges from 6 to 89% depending on the tumor types and method of delivery. Intratumoral injection of IL-12 plasmid DNA in patients with advanced malignant melanoma, 43 and peritumoral injection of IL-12-producing autologous fibroblasts in patients with disseminated cancer 42 have achieved 89% (8/9) and 56% (5/9) response rate, respectively. Currently, there is no clinical trial data available on intramuscular injection of IL-12 plasmid DNA. However, based on our previous and current preclinical studies, 13, 20 it should be able to deliver a therapeutic dose by maintaining a lower but more stable serum IL-12 concentrations, which is in contrast to the sharp peaks and troughs in serum levels after bolus systemic injection. The current study could facilitate a clinical trial of IL-12 gene therapy for poorly differentiated thyroid carcinoma, especially in combination with other treatment strategies.
TGF-β has an important role in tumor initiation and progression. 46 It can function either as a tumor suppressor or a promoter. 47 The mechanisms underlying this dual role of TGF-β remain unclear. There are three TGF-β ligands, TGF-β1, TGF-β2, and TGF-β3. TGF-β1 is the most commonly upregulated ligand in tumor cells. 48 It is well known that TGF-β exerts systemic immune suppression and inhibits host immunosurveillance. 49 Neutralizing TGF-β enhances CD8 + T-and NK cell-mediated antitumor immune responses. 50, 51 Given that TGF-β signaling is upregulated in PTC, 25 it likely has a significant role in the suppression of host immune response against thyroid tumor cells. The current study has confirmed the hypothesis. Furthermore, the immune suppression can be reversed and normal immune response be restored by IL-12 immunotherapy. These data support the application of IL-12 immunotherapy as an adjuvant therapy against PTC.
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